市場調査レポート

世界のアブレーション技術市場(2009年〜2019年):製品・技術・市場・企業・機会

Ablation Technologies Worldwide Market 2009-2019: Products, Technologies, Markets, Companies and Opportunities

発行 MedMarket Diligence, LLC 商品コード 117127
出版日 ページ情報 英文 488 Pages; 123 Exhibits; 76 Profiles
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
世界のアブレーション技術市場(2009年〜2019年):製品・技術・市場・企業・機会 Ablation Technologies Worldwide Market 2009-2019: Products, Technologies, Markets, Companies and Opportunities
出版日: 2010年06月01日 ページ情報: 英文 488 Pages; 123 Exhibits; 76 Profiles

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートでは、軟組織治療のためのアブレーション技術および製品について詳細に分析し、現在および今後の応用分野、現状と将来の予測、南北アメリカ、欧州、アジア太平洋などの地域別市場動向とともに、市場に参入する主な企業の詳細なプロファイルを織り交ぜ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

第1章 エネルギー切除技術で治療する疾患

  • 疾患治療のためのアブレーション技術概要
  • 心血管疾患
  • 眼科
  • 一般外科
  • 婦人科
  • 疼痛管理
  • 泌尿器科
  • 整形外科
  • 美容外科

第2章 製品および技術

  • 凍結療法
  • 電気エネルギー
  • 機械エネルギー
  • 光エネルギー
  • マイクロ波エネルギー
  • 放射線エネルギー
  • 高周波エネルギー
  • 熱エネルギー
  • 超音波エネルギー

第3章 市場評価

  • 世界市場概要
  • 製品別市場セグメンテーション
  • 市場動向
  • 世界市場における主な企業
  • 国別市場
    • 南北アメリカ
    • 欧州
    • アジア太平洋諸国
    • その他

第4章 企業プロファイル

第5章 主な治験

  • 電気
  • 放射線
  • 高周波
  • 超音波
  • 凍結療法
  • マイクロ波
  • 機械

付録

目次
Product Code: A145

This report is a detailed market and technology assessment and forecast of the products and technologies in the ablation market for treatment of soft tissues via energy-based modalities, including electrosurgery, radiosurgery, gamma knife, brachytherapy, cryogenic therapy, fluidjet therapy (hydrotherapy), microwave ablation, radiofrequency ablation, laser, thermal ablation, and ultrasonic ablation.

The report describes alternative energy-based technologies and the nature of their effect on soft tissue, the underlying basis of the technology, the requisite systems for their use (including capital equipment, devices and disposables), and their strengths and weaknesses for specific clinical applications. The report details current and anticipated target applications and assesses the current and forecast caseload for each energy-based therapeutic considering competition from any and all alternative energy-based or other therapeutics, with current and worldwide market forecasts (2009-2018) segmented by technology type and specific clinical segment. The report provides segmentation of the worldwide ablation market by both ablation technology and region/country: Americas (USA, Canada, Mexico, Brazil), Europe (Germany, United Kingdom, France, Italy, Spain, BeNeLux), Asia/Pacific (Japan, China, India, Australia) and Rest of World. The report details the current and emerging products, technologies and markets for each energy-based therapy. The report profiles over 72 key companies in this industry detailing their current products, current market position and products under development.

Table of Contents

Executive Summary

Section 1: DISEASE STATES TREATED WITH ENERGY-BASED ABLATIVE TECHNOLOGY

  • 1.1 Overview of Ablation Technologies for the Treatment of Disease
    • 1.1.1 Electrical
    • 1.1.2 Radiation
    • 1.1.3 Light
      • 1.1.3.1 Lasers and their effect on tissue
      • 1.1.3.2 Photodynamic therapy
    • 1.1.4 Radiofrequency
      • 1.1.4.1 Temperature controlled
      • 1.1.4.2 Fluid cooled
    • 1.1.5 Ultrasound
    • 1.1.6 Cryotherapy
    • 1.1.7 Thermal
    • 1.1.8 Microwave
    • 1.1.9 Hydromechanical
    • 1.1.10 Technologies under development
  • 1.2 Cancer
    • 1.2.1 Breast
      • 1.2.1.1 Current and Emerging Treatment Trends
      • 1.2.1.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.2.2 Liver
      • 1.2.2.1 Current and Emerging Treatment Trends
      • 1.2.2.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.2.3 Lung
      • 1.2.3.1 Current and Emerging Treatment Trends
      • 1.2.3.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.2.4 Prostate
      • 1.2.4.1 Gleason grades and scores
      • 1.2.4.2 Prostate cancer staging
      • 1.2.4.3 Current and Emerging Treatment Trends
      • 1.2.4.4 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.2.5 Kidney
      • 1.2.5.1 Current and Emerging Treatment Trends
      • 1.2.5.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
  • 1.3 Cardiovascular Disease
    • 1.3.1 Angina Pectoris
      • 1.3.1.1 Current and Emerging Treatment Trends
      • 1.3.1.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.3.2 Atrial Arrhythmias
      • 1.3.2.1 Current and Emerging Treatment Trends
      • 1.3.2.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.3.3 Bradycardia
      • 1.3.3.1 Current and Emerging Treatment Trends
      • 1.3.3.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.3.4 Critical Limb Ischemia
      • 1.3.4.1 Current and Emerging Treatment Trends
      • 1.3.4.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.3.5 Critical Ischemic Stroke
      • 1.3.5.1 Current and Emerging Treatment Trends
      • 1.3.5.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.3.6 Hypertension
      • 1.3.6.1 Current and Emerging Treatment Trends
      • 1.3.6.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.3.7 Vascular Occlusive Disease
      • 1.3.7.1 Current and Emerging Treatment Trends
      • 1.3.7.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.3.8 Ventricular Arrhythmias
      • 1.3.8.1 Current and Emerging Treatment Trends
      • 1.3.8.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.3.9 Wolf-Parkinson-White Disease
      • 1.3.9.1 Current and Emerging Treatment Trends
      • 1.3.9.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.3.10 Varicose Veins
      • 1.3.10.1 Current and Emerging Treatment Trends
      • 1.3.10.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
  • 1.4 Ophthalmology
    • 1.4.1 Cataracts
      • 1.4.1.1 Current and Emerging Treatment Trends
      • 1.4.1.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
  • 1.5 General Surgery
    • 1.5.1 Barrett' s Esophagus
      • 1.5.1.1 Current and Emerging Treatment Trends
      • 1.5.1.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.5.2 Fecal Incontinence
      • 1.5.2.1 Current and Emerging Treatment Trends
      • 1.5.2.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.5.3 Gastroesophageal Reflux Disease (GERD)
      • 1.5.3.1 Current and Emerging Treatment Trends
      • 1.5.3.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.5.4 Tonsillectomy
  • 1.6 Gynecology
    • 1.6.1 Menorrhagia
      • 1.6.1.1 Current and Emerging Treatment Trends
      • 1.6.1.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.6.2 Fibroids
      • 1.6.2.1 Current and Emerging Treatment Trends
      • 1.6.2.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.6.3 Stress Incontinence
      • 1.6.3.1 Current and Emerging Treatment Trends
      • 1.6.3.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
  • 1.7 Pain Management
    • 1.7.1.1 Current and Emerging Treatment Trends
    • 1.7.1.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
  • 1.8 Urology
    • 1.8.1 Kidney Stones
      • 1.8.1.1 Current and Emerging Treatment Trends
      • 1.8.1.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.8.2 Benign Prostatic Hypertrophy (BHP)
      • 1.8.2.1 Current and Emerging Treatment Trends
      • 1.8.2.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
  • 1.9 Orthopedics
    • 1.9.1 Joint Instability (conducting Capsular Shrinkage)
      • 1.9.1.1 Current and Emerging Treatment Trends
      • 1.9.1.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.9.2 Carpal Tunnel Syndrome
      • 1.9.2.1 Current and Emerging Treatment Trends
      • 1.9.2.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.9.3 Chondroplasty
      • 1.9.3.1 Current and Emerging Treatment Trends
      • 1.9.3.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.9.4 Debridement
      • 1.9.4.1 Current and Emerging Treatment Trends
      • 1.9.4.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.9.5 Epicondylitis and Tendinitis
      • 1.9.5.1 Current and Emerging Treatment Trends
      • 1.9.5.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.9.6 Nucleoplasty
      • 1.9.6.1 Current and Emerging Treatment Trends
      • 1.9.6.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.9.7 Inflammatory Conditions
      • 1.9.7.1 Current and Emerging Treatment Trends
      • 1.9.7.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
  • 1.10 Aesthetic Treatments
    • 1.10.1 Body Contouring
      • 1.10.1.1 Current and Emerging Treatment Trends
      • 1.10.1.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.10.2 Laser Hair Removal
      • 1.10.2.1 Current and Emerging Treatment Trends
      • 1.10.2.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.10.3 Laser Tattoo Removal
      • 1.10.3.1 Current and Emerging Treatment Trends
      • 1.10.3.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.10.4 Port Wine Stains
      • 1.10.4.1 Current and Emerging Treatment Trends
      • 1.10.4.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.10.5 Psoriasis
      • 1.10.5.1 Current and Emerging Treatment Trends
      • 1.10.5.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues
    • 1.10.6 Scar Reduction and Removal
      • 1.10.6.1 Current and Emerging Treatment Trends
      • 1.10.6.2 Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

Section 2: PRODUCTS AND TECHNOLOGIES

  • 2.1 Cryotherapy
    • 2.1.1 Cardiac Cryoablation System (Cryocor)
    • 2.1.2 Cryospray Ablation System (Csa Medical)
  • 2.2 Electrical Energy
    • 2.2.1 Electrosurgical Ablator
      • 2.2.1.1 OrthoDynamix' ArthroSteer 3.5mm Ablator
    • 2.2.2 Electrical Brachytherapy
  • 2.3 Hydromechanical Energy
  • 2.4 Light Energy
    • 2.4.1 Cold Lasers
    • 2.4.2 Excimer Lasers
      • 2.4.2.1 Spectranetics' Turbo-Tandem System
    • 2.4.3 Photonic Ablation
    • 2.4.4 Ultraviolet B Lasers
    • 2.4.5 Photoselective Vaporisation of the Prostate (PVP) for BHP
    • 2.4.6 HoLAP for BHP
    • 2.4.7 Indigo LaserOptic TreatmentR System for BHP
    • 2.4.8 Laser In-Situ Keratomileusis (LASIK) for Cataracts
    • 2.4.9 Laser Epithelial Keratomileusis (LASEK) for Cataracts
    • 2.4.10 Ablative Fractional Resurfacing (Solta Medical)
  • 2.5 Microwave Energy
    • 2.5.1 CoreTherm for BHP
    • 2.5.2 Prolieve for BHP
  • 2.6 Radiation Energy
    • 2.6.1 Brachytherapy
    • 2.6.2 Stereotactic Radiosurgery (SRS)
      • 2.6.2.1 Cyberknife
      • 2.6.2.2 Gamma Knife
      • 2.6.2.3 Axesse [used for both SRS and SBRT]
      • 2.6.2.4 Novalis
      • 2.6.2.5 Primatom
      • 2.6.2.6 Synergy
      • 2.6.2.7 X-Knife
      • 2.6.2.8 TomoTherapy
      • 2.6.2.9 Trilogy
    • 2.6.3 Stereotactic Body Radiation Therapy (SBRT)
  • 2.7 Radiofrequency Energy
    • 2.7.1 TUNA for BHP
      • 2.7.1.1 Prostiva RF Therapy
    • 2.7.2 RF Ablation Catheters
      • 2.7.2.1 Irrigated
      • 2.7.2.2 Non-Irrigated
  • 2.8 Thermal Energy
    • 2.8.1 TMX 3000 for BHP
    • 2.8.2 Water-Induced Thermotherapy for BHP
  • 2.9 Ultrasonic Energy
    • 2.9.1 Shock Wave Therapy
    • 2.9.2 TUMT for BHP
    • 2.9.3 Ultrasonic Surgical Systems
    • 2.9.4 Spectrasonics' Tissue Parameter Imaging (TPI) technology
    • 2.9.5 Non-invasive transcranial MR-guided focused ultrasound surgery

Section 3: MARKET ASSESSMENT

  • 3.1 World Market Overview
  • 3.2 Market Segmentation by Product Type
  • 3.3 Market Trends
    • 3.3.1 Market Drivers
      • 3.3.1.1 Cardiac Arrhythmias
      • 3.3.1.2 Cancer
      • 3.3.1.3 Healthcare Economics
    • 3.3.2 Market Restraints
      • 3.3.2.1 Procedure Time
      • 3.3.2.2 Cost of Capital Expenditure
      • 3.3.2.3 Recession
  • 3.4 Leading Companies in Global Market
  • 3.5 Major National Markets
    • 3.5.1 Americas
    • 3.5.2 Europe
    • 3.5.3 Asia/Pacific
    • 3.5.4 Rest of World

Section 4: COMPANY PROFILES

  • 4.1 Acoustic MedSystems
  • 4.2 Accuray
  • 4.3 Alcon Laboratories
  • 4.4 American Medical Systems
  • 4.5 Angiodynamics
  • 4.6 Ardian, Inc.
    • 4.6.1 Clinical Trials
      • 4.6.1.1 Symplicity I Trial
      • 4.6.1.2 Symplicity HTN-2 Trial
  • 4.7 ArthroCare Corporation
  • 4.8 AtriCure
    • 4.8.1 Clinical Trials
      • 4.8.1.1 RESTORE SR IIB
  • 4.9 ATS Medical
    • 4.9.1 CryoMaze
  • 4.10 Bard Electrophysiology
    • 4.10.1 Clinical Trials
      • 4.10.1.1 MAGELLAN
  • 4.11 Barrx Medical
  • 4.12 Bausch & Lomb (Warburg Pincus)
  • 4.13 Baylis Medical
  • 4.14 Biocompatibles International plc
  • 4.15 Biosense Webster
    • 4.15.1.1 Irrigated Tip Catheter product lines
    • 4.15.2 Clinical trials
      • 4.15.2.1 NaviStar ThermoCool Catheter for the Treatment of AF - TX Clinical Trial
      • 4.15.2.2 CLARITY Clinical Study
      • 4.15.2.3 Study of a New Catheter Using Force Sensing Capabilities for the Treatment of AF and Ventricular Tachycardia (EZCF-125)
      • 4.15.2.4 NaviStar ThermoCool Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF Clinical Trial
  • 4.16 Biotronik
  • 4.17 Biowave
  • 4.18 Boston Scientific
    • 4.18.1 AFx (Guidant)
  • 4.19 BSD Medical
    • 4.19.1 Phase II MicroThermXR Microwave Ablation System (MTX-180)
    • 4.19.2 BSD 500 Hyperthermia System
    • 4.19.3 BSD-2000
  • 4.20 Cardima
  • 4.21 CardioFocus
    • 4.21.1 Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (CFEAS- AC) for the Treatment of Symptomatic Atrial Fibrillation
  • 4.22 CardioGenesis
  • 4.23 Celon AG
    • 4.23.1 Surgery/Radiology
    • 4.23.2 Phlebology
  • 4.24 Celsion
  • 4.25 Chongqing Haifu (HIFU) Technology Co. Ltd.
  • 4.26 ConMed
  • 4.27 Covidien
    • 4.27.1 Electrosurgery
    • 4.27.2 VNUS Medical Technologies
      • 4.27.2.1 ClosureFAST System
      • 4.27.2.2 Model RFG2 Advanced Radiofrequency Generator
  • 4.28 CryoCath (Medtronic)
  • 4.29 CryoCor
  • 4.30 CryoMedix
  • 4.31 CSA Medical
  • 4.32 Cynosure
  • 4.33 Cytyc
    • 4.33.1 Mammosite
  • 4.34 Dornier MedTech
    • 4.34.1 Compact Delta II
  • 4.35 EDAP TMS S.A.
    • 4.35.1 Ablatherm HIFU
    • 4.35.2 Sonolith ESWL
  • 4.36 Elekta
    • 4.36.1 Leksell Gamma Knife 4
  • 4.37 Endocare
  • 4.38 Endophotonix
  • 4.39 Endosense
    • 4.39.1 TOCCATA Clinical Trial
  • 4.40 Erbe
    • 4.40.1 Electrosurgery
    • 4.40.2 Water Jet Surgery
    • 4.40.3 Cryosurgery
  • 4.41 Ethicon Endo-Surgery
  • 4.42 Focus Surgery
    • 4.42.1 Clinical Trial
      • 4.42.1.1 Organ Confined Prostate Cancer
  • 4.43 Galil Medical
  • 4.44 Getinge Group
    • 4.44.1 Cardiac Surgery
    • 4.44.2 Vascular Surgery
  • 4.45 Gynesonics
  • 4.46 Gyrus ACMI (an Olympus company)
  • 4.47 Halt Medical
    • 4.47.1 Clinical Trial
      • 4.47.1.1 Laparoscopic Radiofrequency Ablation of Symptomatic Uterine Fibroids (Halt Lap RFA)
  • 4.48 HealthTronics Surgical Services
    • 4.48.1 Medical Products
    • 4.48.2 Urology Services
  • 4.49 Hologic, Inc.
  • 4.50 IBt-Bebig, SA
  • 4.51 Initio, Inc.
  • 4.52 InSightec
  • 4.53 Medtronic
    • 4.53.1 Cardiac Rhythm Disease Management (CRDM)
    • 4.53.2 Spinal and Biologics
    • 4.53.3 CardioVascular
    • 4.53.4 Neuromodulation
    • 4.53.5 Diabetes
    • 4.53.6 Surgical Technologies
    • 4.53.7 AF Solutions Franchise
    • 4.53.8 Arctic Front Cardiac CryoAblation Catheter
    • 4.53.9 Cardiac CryoAblation System
    • 4.53.10 Clinical Trials
      • 4.53.10.1 The STOP AF Clinical Trial
      • 4.53.10.2 The TTOP AF Clinical Trial
      • 4.53.10.3 The CURE-AF/Perst Clinical Trial
  • 4.54 Mederi Therapeutics
    • 4.54.1 Secca Procedure for fecal incontinence
    • 4.54.2 Stretta Procedure for GERD
  • 4.55 MedWaves
  • 4.56 Mirabilis Medica
  • 4.57 Misonix
    • 4.57.1 Sonablate
  • 4.58 NeuWave Medical
  • 4.59 Novian Health
    • 4.59.1 Clinical Trials
      • 4.59.1.1 ABLATE (American Breast Laser Ablation Therapy Evaluation)
  • 4.60 NuVue Therapeutics
  • 4.61 Olympus Medical
  • 4.62 OrthoDynamix
  • 4.63 PhotoMedex
  • 4.64 PhotoTherapeutics
  • 4.65 PhotoThera
  • 4.66 Radionics (Integra)
    • 4.66.1 CoolTip RF Electrode
  • 4.67 RFA Medical
  • 4.68 Sanarus Technologies LLC
    • 4.68.1 Cassi II Core Biopsy Device
    • 4.68.2 ImarC Tissue Marker System
    • 4.68.3 Visica 2 Treatment System
    • 4.68.4 Clinical Trials
      • 4.68.4.1 Z1072 Clinical Trial
  • 4.69 Sirtex Medical
  • 4.70 Smith & Nephew
    • 4.70.1 Dyonics RF System
  • 4.71 Solta Medical
    • 4.71.1 Ablative Fractional Resurfacing
  • 4.72 Spectranetics
  • 4.73 Spectrasonics
  • 4.74 St. Jude Medical
    • 4.74.1 Atrial Fibrillation
      • 4.74.1.1 CABANA Clinical Trial
      • 4.74.1.2 IRASE AF Clinical Trial
      • 4.74.1.3 Modified stepwise Ablation Guided by low dose Ibutilide Use in Chronic Atrial Fibrillation Trial (MAGIC-AF)
      • 4.74.1.4 AFMAZE-CABG Clinical Trial
  • 4.75 Starion Instruments
  • 4.76 Stereotaxis
    • 4.76.1 Stereotaxis Magnetic Navigation System
  • 4.77 Synapse Biomedical
  • 4.78 Theragenics
  • 4.79 Urologix
    • 4.79.1 Targis System
  • 4.80 USHIFU
  • 4.81 Varian Medical Systems
    • 4.81.1 RapidArc
    • 4.81.2 Dynamic Targeting Image-Guided Radiation Therapy (IGRT)
    • 4.81.3 SmartBeam IMRT
    • 4.81.4 On-Board Imager
    • 4.81.5 Dynamic Adaptive Radiotherapy (DART)
    • 4.81.6 Image-Guided Brachytherapy (IGBT)
    • 4.81.7 Varian Proton Therapy System
  • 4.82 Visualase
  • 4.83 Urologix

Section 5: key CLINICAL TRIALS

  • 5.1 Electrical
  • 5.2 Radiation
  • 5.3 Light
    • 5.3.1 Novian Health
      • 5.3.1.1 ABLATE (American Breast Laser Ablation Therapy Evaluation)
    • 5.3.2 CardioFocus
    • 5.3.3 EndoPhotoniX
  • 5.4 RadioFrequency
    • 5.4.1 Ardian, Inc.
      • 5.4.1.1 Symplicity I Trial
      • 5.4.1.2 Symplicity HTN-2 Trial
    • 5.4.2 AtriCure
    • 5.4.3 Bard Electrophysiology
    • 5.4.4 Biosense Webster
      • 5.4.4.1 NaviStar ThermoCool Catheter for the Treatment of AF - TX Clinical Trial
      • 5.4.4.2 CLARITY Clinical Study
      • 5.4.4.3 Study of a New Catheter Using Force Sensing Capabilities for the Treatment of AF and Ventricular Tachycardia (EZCF-125)
      • 5.4.4.4 NaviStar ThermoCool Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF Clinical Trial
    • 5.4.5 Halt Medical
      • 5.4.5.1 Laparoscopic Radiofrequency Ablation of Symptomatic Uterine Fibroids (Halt Lap RFA)
    • 5.4.6 Medtronic
      • 5.4.6.1 The CURE-AF/Perst Clinical Trial
      • 5.4.6.2 The TTOP AF Clinical Trial
    • 5.4.7 St. Jude Medical
      • 5.4.7.1 CABANA Clinical Trial
      • 5.4.7.2 IRASE AF Clinical Trial
      • 5.4.7.3 Modified stepwise Ablation Guided by low dose Ibutilide Use in Chronic Atrial Fibrillation Trial (MAGIC-AF)
  • 5.5 Ultrasound
    • 5.5.1 St. Jude Medical
      • 5.5.1.1 AFMAZE-CABG Clinical Trial
  • 5.6 Cryotherapy
    • 5.6.1 Medtronic
      • 5.6.1.1 The STOP AF Clinical Trial
    • 5.6.2 Sanarus Medical Technologies LLC
      • 5.6.2.1 Z1072 Clinical Trial
  • 5.7 Thermal
  • 5.8 Microwave
  • 5.9 Hydromechanical

APPENDIX I: COMPANY DIRECTORY

APPENDIX II: RELEVANT ORGANIZATIONS

APPENDIX III: ABBREVIATIONS USED IN THIS REPORT

Back to Top